Master Alliance Provisions Guide (MAPGuide)

NIH – UniQure, AAV5 Gene Therapies Exclusive and Non-Exclusive License Agreement

  • Business model | Governance



14.12 The parties agree to attempt to settle amicably any controversy or claim arising under this Agreement or a breach of this Agreement, except for appeals of modifications or termination decisions provided for in Article 13. Licensee agrees first to appeal any unsettled claims or controversies to the designated PHS official, or designee, whose decision shall be considered the final agency decision. Thereafter, Licensee may exercise any administrative or judicial remedies that may be available.